CVS Health
CVS
$95.55
+0.94%
CVS Health Corporation is a diversified healthcare enterprise whose operations span retail pharmacy (roughly 9,000 U.S. stores), a large pharmacy benefit manager (Caremark, processing about 2 billion adjusted claims annually), a top-tier health insurer (Aetna, serving roughly 26 million medical members), and primary care assets added through the Oak Street Health acquisition. Its vertically integrated model — pairing drug purchasing and dispensing, benefits administration, and medical insurance under one roof — makes it distinct among managed care peers, which typically lack a retail and PBM footprint of comparable scale. The current investor narrative centers on a credible turnaround: a lower medical cost ratio and a stronger-than-expected Q1 profit print drove a raised full-year outlook, while a favorable CMS Medicare Advantage payment decision added roughly $13 billion of revenue visibility and helped close what bulls describe as a valuation gap versus peers. Offsetting this optimism, the debate remains anchored on persistent pharmacy reimbursement pressure, regulatory scrutiny of PBM practices, and whether AI-driven operational improvements and consumer wellness initiatives can sustain margin recovery beyond the near term.…
CVS
CVS Health
$95.55
Related headlines
Investment Opinion: Should I buy CVS Today?
The synthesized recommendation for CVS is a Buy, anchored by a strong buy consensus from 25 analysts and an average target price of $116.04, which implies 22.6% upside from the current price of $94.66. The core thesis is that the market is undervaluing a credible earnings recovery, with a forward PE of 11.12x against estimated EPS of $11.82, and the stock offers a rare combination of deep value and defensive characteristics (beta 0.58). The unanimous analyst support, with even the lowest target at $103.00 (8.8% above current), reinforces the favorable risk/reward.
Supporting evidence includes revenue growth of 6.17% year over year in Q1 2026 to $100.43 billion, a significant improvement in profitability from the Q3 2025 loss to $2.94 billion net income in Q1 2026, and trailing free cash flow of $7.39 billion that comfortably covers the $847 million quarterly dividend and $1.52 billion debt repayment. The forward PE of 11.12x is well below the industry average for managed care peers, and the PS ratio of 0.25x confirms the stock is priced for a low-margin, high-volume business. The $13 billion Medicare Advantage revenue tailwind adds further visibility to the earnings recovery.
Key risks that could invalidate the thesis include a reversal in the medical cost ratio improvement, regulatory action against the PBM segment, and a failure to sustain margin expansion beyond the near term. The rating would upgrade to a Strong Buy if the stock breaks above the 52-week high of $110.68 on strong volume, or downgrade to a Hold if revenue growth decelerates below 5% or if the medical cost ratio deteriorates in the next quarter. Relative to its own history, the forward PE of 11.12x is near the low end of its historical range, and the stock appears undervalued given the earnings recovery potential, though the trailing PE of 56.69x is an outlier due to the loss quarter.
Sign up to view all
CVS 12-Month Price Forecast
The forward-looking view on CVS is bullish, supported by a deep value forward PE of 11.12x, a strong buy consensus from 25 analysts, and a $13 billion Medicare Advantage revenue tailwind. The company's $7.39 billion free cash flow and 3.38% dividend yield provide a margin of safety, while the low beta of 0.58 makes it an attractive defensive holding. However, confidence is medium due to persistent reimbursement pressures and regulatory risks that could delay the earnings recovery. An upgrade to high confidence would require two consecutive quarters of medical cost ratio improvement and clarity on PBM regulation. A downgrade to bearish would occur if the medical cost ratio reverses or if revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $116.28 and implied upside of +21.7% versus the current price.
Average Target
$116.28
0 analysts
Implied Upside
+21.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $148
Analyst target range
Coverage is robust with 25 analysts, and sentiment is decisively bullish: the consensus recommendation is strong_buy with a recommendation mean of 1.44 (where 1.0 is a strong buy), and the average target price of $116.04 implies roughly 22.6% upside from the current price of $94.66. Notably, even the lowest target of $103.00 sits about 8.8% above the current price, meaning no analyst in the coverage universe sees downside from here — an unusually strong signal of conviction. The consensus leans firmly bullish, supported by a steady stream of reaffirmed Overweight and Buy ratings from major firms including Wells Fargo, RBC Capital, Cantor Fitzgerald, B of A Securities, Mizuho, Morgan Stanley, Truist, and Barclays between May and July 2026, with no downgrades in the institutional ratings history. The target range spans $103.00 to $148.00, a spread of $45.00 or roughly 44% of the low target, which signals meaningful dispersion in outcome assumptions. The high target of $148.00 implies about 56.4% upside and likely assumes successful margin expansion, full realization of the $13 billion Medicare payment benefit, AI-driven cost efficiencies, and multiple re-rating toward peer levels; the low target of $103.00 implies a more conservative scenario of modest earnings recovery with continued reimbursement pressure and regulatory overhang capping upside. The tight clustering of recent ratings at Overweight/Buy with no downgrades, combined with a consensus EPS estimate of $11.82 (range $11.40 to $12.30) and revenue estimate of $490.99 billion, suggests analysts have high confidence in the near-term earnings trajectory even as the wide price-target spread reflects uncertainty about the pace of the longer-term margin recovery.
Drowning in data?
Find the real signal!
Bulls vs Bears: CVS Investment Factors
The bull case for CVS rests on a credible earnings recovery story: a forward PE of 11.12x, a strong buy consensus with 22.6% upside to the average target, and a $13 billion Medicare Advantage revenue tailwind. The bear case centers on structural margin pressure from pharmacy reimbursement, regulatory overhang on the PBM, and recent momentum deterioration that has pushed the stock down 6.33% over the past month. Currently, the bull evidence is stronger, given the unanimous analyst support, no downside in the target range, and robust free cash flow of $7.39 billion that funds both dividends and debt reduction. The single most important tension is whether the insurance margin recovery can be sustained beyond the near term; if medical cost ratios continue to improve, the forward earnings multiple is likely to re-rate higher, but if reimbursement pressure intensifies, the stock could retest its 52-week low of $69.51.
Bullish
- Deep Value on Forward Earnings: CVS trades at a forward PE of just 11.12x against consensus EPS of $11.82, a steep discount to the broader market and managed care peers. The trailing PE of 56.69x is distorted by a prior-year loss quarter, and the gap implies the Street expects earnings to roughly quintuple as insurance margins normalize.
- Analyst Consensus Strong Buy with No Downside: All 25 covering analysts rate CVS a strong buy (mean 1.44), with an average target of $116.04 implying 22.6% upside. Even the lowest target of $103.00 sits 8.8% above the current price, an unusually strong signal that no analyst sees downside from here.
- Medicare Advantage Tailwind Adds $13B Revenue: A favorable CMS 2027 Medicare Advantage payment decision added roughly $13 billion in revenue visibility, directly boosting the Aetna insurance segment. This regulatory win improves the earnings recovery trajectory and reduces policy uncertainty for the next several years.
- Cash Generation Funds Dividends and Deleveraging: Trailing free cash flow is $7.39 billion, with Q1 2026 FCF of $3.40 billion on operating cash flow of $4.25 billion against only $849 million of capex. The company returned $847 million in dividends and repaid $1.52 billion of debt in the quarter, demonstrating self-funding capital returns.
Bearish
- Persistent Pharmacy Reimbursement Pressure: CVS's core pharmacy and PBM segments face ongoing reimbursement headwinds that cap margin expansion. Gross margin remains structurally low at 15.56% in Q1 2026, and the company's 2.93% net margin leaves little cushion for further rate compression.
- Regulatory Scrutiny of PBM Practices: Caremark, CVS's PBM, processes about 2 billion adjusted claims annually and is a target of increasing regulatory scrutiny over drug pricing and rebate practices. Any adverse legislation or enforcement action could materially impact the profitability of this high-volume segment.
- Earnings Volatility and Thin Margins: CVS reported a Q3 2025 net loss of $3.98 billion (-3.86% net margin) driven by a $17.01 billion operating expense line and negative EBITDA of $1.56 billion. This volatility highlights the earnings risk inherent in the insurance underwriting and pharmacy distribution businesses.
- Leverage and Weak Balance Sheet Metrics: Debt-to-equity stands at 1.24, and the current ratio is a thin 0.84, below 1.0, reflecting working-capital-heavy operations. ROE is just 2.35% and ROA 2.97%, both depressed by the prior-year loss quarter, indicating weak near-term profitability relative to the balance sheet.
CVS Technical Analysis
CVS is in a broad recovery uptrend that has cooled into a consolidation phase: the stock is up 26.77% over the past year and 18.13% year-to-date, yet at $94.66 it sits roughly 60.5% of the way through its 52-week range of $69.51 to $110.68 — closer to the top than the bottom but still about 14.5% below the 52-week high. That positioning suggests the powerful April–July advance has stalled rather than reversed, leaving the stock in a digestion phase where momentum buyers have stepped back but the longer-term trend structure remains intact. The 52-week low of $69.51 was set in late March, and the subsequent rally of more than 59% off that low confirms a genuine trend change rather than a dead-cat bounce. Recent momentum, however, has turned negative and is diverging from the longer-term trend: the stock is down 6.33% over the past month and 7.16% over three months, even as the 1-year change remains +26.77%. Relative strength tells the same story of deceleration — CVS outperformed SPY by 10.55 percentage points over 1 year and 6.05 points YTD, but underperformed by 10.20 points over the past 3 months and is essentially flat over 1 month (relative strength of 0.9967 versus SPY's -1.06% move). This 1-month/3-month weakness against a positive 1-year trend is characteristic of a mean-reversion pullback within an uptrend rather than a confirmed reversal, though the failure to hold above $100 keeps the burden of proof on the bulls. Key levels are well defined: resistance sits at the 52-week high of $110.68, and a decisive breakout above that level would signal renewed institutional accumulation and likely open a move toward the analyst consensus target zone; support rests at the 52-week low of $69.51, with intermediate support around the $92–93 area where the stock has repeatedly found buyers in August and September. A beta of 0.58 means CVS is roughly 42% less volatile than the broader market, which is unusually defensive for an equity and argues for larger position sizing on a risk-adjusted basis, while the 16.44% maximum drawdown over the period underscores that even low-beta names carry meaningful downside when sentiment shifts.
Beta
0.58
0.58x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$70-$111
Price range past year
Annual Return
+27.4%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -1.7% | -2.0% |
| 3m | -5.1% | +1.4% |
| 6m | +30.9% | +15.0% |
| 1y | +27.4% | +15.7% |
| ytd | +19.2% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
Revenue is growing at a healthy clip for a company of this scale: Q1 2026 revenue reached $100.43 billion, up 6.17% year over year from $94.59 billion in Q1 2025, extending a multi-quarter expansion that has carried quarterly revenue from $91.23 billion in Q2 2024 to above $100 billion. The sequential trend is choppy — Q4 2025 revenue of $105.69 billion was the peak, and Q1 2026 came in slightly lower — but the year-over-year trajectory remains firmly positive, with the pharmacy segment ($56.94 billion) and premiums ($33.79 billion) as the dominant revenue engines, dwarfing front-store revenue of $5.26 billion and corporate/other of $126 million. This mix means the investment case is driven overwhelmingly by PBM volumes and insurance membership economics rather than retail foot traffic, so reimbursement rates and medical cost trends matter far more than store-level sales. Profitability is thin but improving: Q1 2026 net income was $2.94 billion on a 2.93% net margin, with gross margin of 15.56% and operating margin of 4.66%, a marked recovery from the Q3 2025 loss of $3.98 billion (a -3.86% net margin quarter driven by a $17.01 billion operating expense line and negative EBITDA of $1.56 billion). Gross margin has oscillated in a narrow band — 12.84% in Q4 2025, 13.42% in Q3 2025, 15.56% in Q1 2026 — and the sequential improvement alongside a lower medical cost ratio is the core of the turnaround thesis, though at roughly 15% gross margin CVS remains structurally low-margin, as is typical for a business blending low-margin pharmacy distribution with insurance underwriting. The balance sheet carries meaningful leverage but manageable coverage: debt-to-equity stands at 1.24, the current ratio is a thin 0.84 (below 1.0, reflecting the working-capital-heavy nature of pharmacy and insurance operations), and ROE is just 2.35% with ROA of 2.97%, both depressed by the prior-year loss quarter. Cash generation is the strongest part of the story — trailing free cash flow is $7.39 billion, Q1 2026 free cash flow was $3.40 billion on operating cash flow of $4.25 billion against $849 million of capex, and the company returned $847 million in dividends during the quarter while repaying $1.52 billion of debt, demonstrating that internal cash flow comfortably funds both shareholder returns and deleveraging without external financing.
Quarterly Revenue
$100.4B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
15.6%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Because CVS is profitable — Q1 2026 net income of $2.94 billion and trailing EPS of $0.0176 — the PE ratio is the appropriate primary metric, though the trailing figure is distorted by the prior-year loss quarter. The trailing PE of 56.69x is optically extreme and reflects the depressed trailing earnings base, while the forward PE of 11.12x against consensus estimated EPS of $11.82 tells the real story: the market is pricing a dramatic earnings recovery, with the gap between 56.7x trailing and 11.1x forward implying the Street expects earnings to roughly quintuple as the insurance unit normalizes and cost pressures ease. The PS ratio of 0.25x and EV/Sales of 0.447x confirm that on a revenue basis the stock is priced for a low-margin, high-volume business rather than a premium multiple. Relative to the healthcare plans industry, CVS screens as a deep value proposition: a forward PE of 11.1x and PS of 0.25x are well below what managed care peers typically command, and the PEG ratio of -0.92 (negative due to the trailing earnings distortion) is not meaningful here. The discount appears justified in part by CVS's structurally lower gross margin (15.56%) versus pure-play insurers, its PBM regulatory overhang, and its 1.24 debt-to-equity leverage, but the forward multiple suggests the market is not yet crediting the full earnings recovery — a gap that bulls argue is the core mispricing. Historically, CVS has traded in a wide PE band: 7.77x in Q1 2026, 8.55x in Q4 2025, 12.01x in Q1 2025, and as high as 22.60x in Q1 2024, with the current trailing 56.69x an outlier driven by the loss quarter rather than a genuine re-rating. On price-to-book, the current 1.34x sits mid-range versus 1.18x in Q1 2026, 0.75x in Q4 2024, and 1.71x in Q4 2022, suggesting the stock is neither at a historical valuation extreme nor obviously cheap on book value — the valuation case rests almost entirely on the forward earnings recovery materializing.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
CVS faces financial and operational risks rooted in its thin margins and leveraged balance sheet. The company's net margin is just 2.93% in Q1 2026, and gross margin of 15.56% leaves little room for error if reimbursement rates decline or medical costs rise. Debt-to-equity of 1.24 and a current ratio of 0.84 indicate that the company relies on steady cash flow to manage working capital and service obligations, and any disruption to its $7.39 billion trailing free cash flow could strain liquidity. Additionally, the Q3 2025 loss of $3.98 billion demonstrates that earnings can swing violently due to insurance underwriting volatility, making the recovery less predictable than the forward PE suggests.
Market and competitive risks include valuation compression if the earnings recovery disappoints, given the stock's forward PE of 11.12x already prices in a substantial rebound. With a beta of 0.58, CVS is less sensitive to broad market swings, but it remains exposed to sector-specific headwinds such as regulatory scrutiny of PBM practices and potential drug pricing reforms. Recent news highlights that persistent reimbursement pressures and regulatory challenges make the stock a hold for now, despite operational improvements and AI integration. Competitive threats from pure-play insurers and retail pharmacies could also erode CVS's vertically integrated advantage, particularly if peers adopt similar models at lower cost structures.
The worst-case scenario would involve a combination of regulatory action against Caremark's PBM practices, a resurgence in medical cost ratios that reverses the Q1 2026 improvement, and a broader market rotation away from healthcare. In this scenario, the stock could retest its 52-week low of $69.51, representing a decline of approximately 26.6% from the current price of $94.66. The maximum drawdown over the past period was 16.44%, but a more severe outcome could push the stock toward the analyst low target of $103.00, which is still above the current price, suggesting that even the bear case from analysts does not envision a return to the lows. However, if the recovery thesis unravels, the stock could fall below $80, implying a loss of 15-20% from current levels.
FAQ
The most severe risk is regulatory action against CVS's PBM, Caremark, which processes about 2 billion adjusted claims annually; adverse legislation could compress margins significantly. Financial risks include high leverage with a debt-to-equity of 1.24 and a thin current ratio of 0.84, leaving little room for error if cash flow declines. Operational risks stem from earnings volatility, as evidenced by the Q3 2025 net loss of $3.98 billion, and the potential for medical cost ratios to reverse their recent improvement. Competitive risks include pressure from pure-play insurers and retail pharmacies, as well as the possibility that the vertically integrated model fails to deliver expected synergies. Macro risks are mitigated by the low beta of 0.58, but sector rotation away from healthcare could still weigh on the stock.
The 12-month forecast for CVS includes three scenarios: a bull case with 30% probability targeting $130-148, a base case with 50% probability targeting $110-120, and a bear case with 20% probability targeting $69.51-85. The base case is most likely, assuming the company meets consensus EPS of $11.82 and revenue of $490.99 billion, supported by the $13 billion Medicare Advantage tailwind. The bull case requires successful margin expansion and multiple re-rating, while the bear case would be triggered by a reversal in medical cost ratios or adverse PBM regulation. The average analyst target of $116.04 aligns with the base case, implying 22.6% upside from the current price of $94.66.
CVS appears undervalued on a forward earnings basis, trading at a forward PE of 11.12x compared to a trailing PE of 56.69x, which reflects a depressed earnings base. The PS ratio of 0.25x and EV/Sales of 0.447x indicate the market is pricing the stock as a low-margin, high-volume business, well below typical managed care peers. Relative to its own history, the forward PE is near the low end of its range, while the price-to-book ratio of 1.34x is mid-range. The market appears to be discounting the earnings recovery, implying skepticism about margin expansion. If the recovery materializes, the multiple could re-rate toward 15x, suggesting significant upside.
From a risk/reward perspective, CVS appears attractive for value-oriented investors, with a forward PE of 11.12x and a strong buy consensus from 25 analysts. The average target price of $116.04 implies 22.6% upside, and even the lowest target of $103.00 is 8.8% above the current price, suggesting limited downside according to analysts. The biggest downside risk is a retest of the 52-week low of $69.51, which would represent a 26.6% loss, but this seems unlikely given the improving earnings trajectory. For income investors, the 3.38% dividend yield and $7.39 billion free cash flow provide comfort. However, the stock is best suited for those with a medium to long-term horizon who can tolerate regulatory and reimbursement uncertainties.
CVS is more suitable for long-term investment, given its turnaround narrative, defensive beta of 0.58, and dividend yield of 3.38%. The earnings recovery is expected to unfold over multiple quarters, and short-term trading would be exposed to volatility from quarterly earnings and regulatory news. The stock's low beta and stable cash flows make it appropriate for income-oriented portfolios with a minimum holding period of 12-18 months to allow the margin recovery to materialize. Short-term traders might find opportunities around earnings releases, but the risk/reward favors a patient approach. The current consolidation phase, with the stock down 6.33% over the past month, could offer an entry point for long-term investors.
